An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...
Once-daily orforglipron induced greater reductions in HbA1c and body weight than once-daily oral semaglutide for adults with type 2 diabetes, according to data from the ACHIEVE-3 trial published in ...
WAN CHAI, WAN CHAI, HONG KONG, January 23, 2026 /EINPresswire.com/ — Even with the advancement of Automated Insulin Delivery (AID) technologies, diabetes management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results